Drug Trial Radar · NCT07692165
A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
Jun 11, 2026
Primary completion
Jun 2028
Study completion Jun 2028
Sponsor
- Lead sponsor
- Innatus Therapeutics (Shanghai) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multicenter, Randomized, Open-label Clinical Study to Evaluate the Safety and Efficacy of INT-210 Capsules in Participants with Active Ulcerative Colitis. The study aims to evaluate the safety, efficacy, pharmacokinetic (PK) characteristics, pharmacodynamic (PD) characteristics of INT-210 in participants with active ulcerative colitis (UC).
Conditions
- Ulcerative Colitis (UC)
Interventions
INT-210 CapsuleDrug
All participants will receive oral treatment with INT-210 capsule 200 mg twice daily, starting from Day 1 (D1) of the treatment period (12 weeks).
INT-210 CapsuleDrug
All participants will receive oral treatment with INT-210 capsule 400 mg twice daily, starting from Day 1 (D1) of the treatment period (12 weeks)
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of treatment-emergent adverse eventsTime frame: From enrollment through the safety follow-up visit on Day 92
- Treatment-emergent potentially clinically- significant abnormalities in safety laboratory parameters-hematologyTime frame: From enrollment through the safety follow-up visit on Day 92
- Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: blood chemistryTime frame: From enrollment through the safety follow-up visit on Day 92
- Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: serum ferritinTime frame: From enrollment through the safety follow-up visit on Day 92
- Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: coagulationTime frame: From enrollment through the safety follow-up visit on Day 92
- Treatment-emergent potentially clinically significant abnormalities in safety laboratory parameters: urinalysisTime frame: From enrollment through the safety follow-up visit on Day 92
- Treatment-emergent potentially clinically significant abnormalities in electrocardiogram values: QTcF (milliseconds)Time frame: From enrollment through the safety follow-up visit on 92
- Treatment-emergent potentially clinically significant abnormalities in vital signs: heart rate (beats per minute)Time frame: From enrollment through the safety follow-up visit on Day 92
- Treatment-emergent potentially clinically significant abnormalities in vital signs: blood pressure (mmHg)Time frame: From enrollment through the safety follow-up visit on Day 92
- Treatment-emergent potentially clinically significant abnormalities in vital signs: respiration rate (BPM)Time frame: From enrollment through the safety follow-up visit on Day 92
- Treatment-emergent potentially clinically significant abnormalities in vital signs: temperature (℃)Time frame: From enrollment through the safety follow-up visit on Day 92
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chao-Yang Hospital, Capital Medical University
Beijing, China · Recruiting
Beijing Friendship Hospital, Capital Medical University
Beijing, China · Recruiting
Beijing Luhe Hospital, Capital Medical University
Beijing, China · Recruiting
Guangzhou First People's Hospital
Guangzhou, China · Recruiting
The First Affiliated Hospital, Sun Yat-sen University
Guangzhou, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, China · Recruiting
XinHua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, China · Recruiting
Shanxi Bethune Hospital
Taiyuan, China · Recruiting
Weifang People's Hospital
Weifang, China · Recruiting
The Second Affiliated Hospital of Wenzhou Medical University
Wenzhou, China · Recruiting
Renmin Hospital of Wuhan University
Wuhan, China · Recruiting
Xijing Hospital (The First Affiliated Hospital of Air Force Medical University)
Xi'an, China · Recruiting
The First Affiliated Hospital of Henan Medical University
Xinxiang, China · Recruiting
The Sixth Affiliated Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.